Show Search Form
human indexable | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
published | |||||||||||
registered interest | |||||||||||
answer date | |||||||||||
date | |||||||||||
date tabled | |||||||||||
ddp created | |||||||||||
answering body |
|
||||||||||
question status | Tabled | ||||||||||
answering dept id | 17 | ||||||||||
answering dept short name | Health and Social Care | ||||||||||
answering dept sort name | Health and Social Care | ||||||||||
ddp modified |
|
||||||||||
hansard heading | IVF: Breast Cancer | ||||||||||
house id | 2 | ||||||||||
identifier | HL16733 | ||||||||||
legislature |
|
||||||||||
parliament number | 57 | ||||||||||
question first answered |
|
||||||||||
question text | To ask Her Majesty's Government, further to the Written Answers by the Parliamentary Under-Secretary of State for Health on 14 July 2014 (HC Deb, col 448W), Earl Howe on 3 December 2014 (HL273), Lord O'Shaughnessy on 3 December 2018 (HL11600), and comments by the Parliamentary Under-Secretary of State for Health on 20 January 2016 (HC Deb, col 623WH), to what extent the Human Fertilisation and Embryology Authority (HFEA) database is linked to (1) NHS databases, and (2) cancer registries; whether data from the register of patients and treatments that is maintained by the HFEA is sufficient to assess the contention that IVF in older women linked to an increased risk of breast cancer; and how the HFEA will ensure that information provided to patients regarding any potential long-term safety implications associated with treatment will include appropriate reference to such risks. | ||||||||||
session |
|
||||||||||
session number | 1 | ||||||||||
tabling member printed |
|
||||||||||
title | House of Lords Tabled Parliamentary Question 2017/19 HL16733 | ||||||||||
type |
|
||||||||||
uin | HL16733 | ||||||||||
version | 1 | ||||||||||
written parliamentary question type | Ordinary | ||||||||||
answer | answer | ||||||||||
creator |
|
||||||||||
publisher | 25277 | ||||||||||
tabling member |
|
human indexable | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
published | |||||||||||
registered interest | |||||||||||
answer date | |||||||||||
date | |||||||||||
date tabled | |||||||||||
ddp created | |||||||||||
answering body |
|
||||||||||
question status | Tabled | ||||||||||
answering dept id | 17 | ||||||||||
answering dept short name | Health and Social Care | ||||||||||
answering dept sort name | Health and Social Care | ||||||||||
ddp modified |
|
||||||||||
hansard heading | IVF: Drugs | ||||||||||
house id | 2 | ||||||||||
identifier | HL16734 | ||||||||||
legislature |
|
||||||||||
parliament number | 57 | ||||||||||
question first answered |
|
||||||||||
question text | To ask Her Majesty's Government, further to the Written Answers by the Parliamentary Under-Secretary of State for Health on 14 July 2014 (HC Deb, col 448W), Earl Howe on 3 December 2014 (HL273), and comments by the Parliamentary Under-Secretary of State for Health on 20 January 2016 (HC Deb, col 623WH), how the Human Fertilisation and Embryology Authority (HFEA) ensures that clinics follow National Institute for Health and Care Excellence guidelines on limiting the use of ovulation induction or ovarian stimulation agents to the lowest effective dose and duration of use without collecting information on the identity of drugs used in treatment, the dosage used and the associated regimen for ovarian stimulation at each licensed centre; and what would be needed for the HFEA to regulate the administration of drugs during in vitro fertilisation treatment. | ||||||||||
session |
|
||||||||||
session number | 1 | ||||||||||
tabling member printed |
|
||||||||||
title | House of Lords Tabled Parliamentary Question 2017/19 HL16734 | ||||||||||
type |
|
||||||||||
uin | HL16734 | ||||||||||
version | 1 | ||||||||||
written parliamentary question type | Ordinary | ||||||||||
answer | answer | ||||||||||
creator |
|
||||||||||
publisher | 25277 | ||||||||||
tabling member |
|